Literature DB >> 33530381

Intestinal Microbiota and Perspectives of the Use of Meta-Analysis for Comparison of Ulcerative Colitis Studies.

Ivan Kushkevych1, Kristýna Martínková1, Monika Vítězová1, Simon K-M R Rittmann2.   

Abstract

Meta-analysis is a statistical process summarizing comparable data from a number of scientific papers. The use of meta-analysis in microbiology allows decision-making that has an impact on public health policy. It can happen that the primary researches come to different conclusions, although these are targeted with the same research question. It is, therefore, inevitable to have the means to systematically evaluate information and compare research results. Ulcerative colitis together with Crohn's disease are among the two main inflammatory bowel diseases. This chronic disease of the gastrointestinal tract, with an as yet unclear etiology, is presented by an uncontrolled inflammatory immune response in genetically predisposed individuals to as yet undefined environmental factors in interaction with the intestinal microbiota itself. In patients with ulcerative colitis (UC), changes in the composition and relative abundance of microorganisms could be observed. Sulfate-reducing bacteria (SRB), which commonly occur in the large intestine as part of the commensal microbiota of animals and humans involved in the pathogenesis of the disease, have been shown to occur. SRB are anaerobic organisms affecting short-chain fatty acid metabolism. This work outlines the perspectives of the use of meta-analysis for UC and changes in the representation of intestinal organisms in these patients.

Entities:  

Keywords:  hydrogen sulfide; inflammatory bowel diseases; intestinal microbiome; meta-analysis; sulfate-reducing bacteria; ulcerative colitis

Year:  2021        PMID: 33530381     DOI: 10.3390/jcm10030462

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  5 in total

1.  SlpB Protein Enhances the Probiotic Potential of L. lactis NCDO 2118 in Colitis Mice Model.

Authors:  Giovanna A Belo; Bárbara F Cordeiro; Emiliano R Oliveira; Marina P Braga; Sara H da Silva; Bruno G Costa; Flaviano Dos S Martins; Gwénaël Jan; Yves Le Loir; Alfonso Gala-García; Enio Ferreira; Vasco Azevedo; Fillipe L R do Carmo
Journal:  Front Pharmacol       Date:  2021-12-20       Impact factor: 5.810

2.  Kui Jie Tong Ameliorates Ulcerative Colitis by Regulating Gut Microbiota and NLRP3/Caspase-1 Classical Pyroptosis Signaling Pathway.

Authors:  Shigui Xue; Yan Xue; Danbo Dou; Huan Wu; Ping Zhang; Yang Gao; Yini Tang; Zehua Xia; Sen Yang; Sizhen Gu
Journal:  Dis Markers       Date:  2022-07-04       Impact factor: 3.464

3.  Development of microparticles for oral administration of Periplaneta americana extract to treat ulcerative colitis.

Authors:  Meng Li; Hao Wu; Shuang Wang; Shengshun Wu; Jing Han; Yang Han
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

4.  Epigenetic DNA Methylation of EBI3 Modulates Human Interleukin-35 Formation via NFkB Signaling: A Promising Therapeutic Option in Ulcerative Colitis.

Authors:  Alexandra Wetzel; Bettina Scholtka; Fabian Schumacher; Harshadrai Rawel; Birte Geisendörfer; Burkhard Kleuser
Journal:  Int J Mol Sci       Date:  2021-05-19       Impact factor: 5.923

5.  Desulfovibrio desulfuricans AY5 Isolated from a Patient with Autism Spectrum Disorder Binds Iron in Low-Soluble Greigite and Pyrite.

Authors:  Olga V Karnachuk; Olga P Ikkert; Marat R Avakyan; Yurii V Knyazev; Mikhail N Volochaev; Viacheslav S Zyusman; Vasily L Panov; Vitaly V Kadnikov; Andrey V Mardanov; Nikolai V Ravin
Journal:  Microorganisms       Date:  2021-12-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.